Vaccines Market

How big is the Vaccines Market in 2026?

Demand for preventive immunisation is projected to bring the Vaccines Market to USD 119.5 billion by 2036. FMI assesses the market at USD 58.5 billion in 2026 and projects a 7.4% CAGR from 2026 to 2036. The market was valued at USD 54.5 billion in 2025. Human Use holds 68.2% by application in 2026. Subunit & Conjugate vaccines account for 24.7% by vaccine type, and Injectable products represent 93.0% by route of administration in FMI's 2026 assessment.

Funded childhood schedules and new adult programmes shape the outlook. The World Health Organization reported three-dose DTP coverage of 85.0% of infants in 2025 and counted 162 countries with HPV vaccination in their national programmes [1]. UNICEF shipped 3.2 billion doses of vaccine into 103 countries during the same year and spent USD 2.4 billion on them [2]. Adult respiratory immunisation adds a second buying cycle. Six EU countries secured RSV vaccine access through a European Commission contract in July 2026 that runs to 24.0 million doses [5].

Shifts in national recommendations are the main restraint. The US Centers for Disease Control and Prevention cut the list of vaccines recommended for all children to 11 diseases in January 2026 [3]. Pfizer offers a qualified example [4]. Its Prevnar family revenue fell 10.0% to USD 1,564.0 million in third-quarter 2026 on lower US vaccination rates. One product line does not define the market, but it shows how policy moves demand within a season.

Key Market Trends & Insights

• Older-adult pneumococcal schedules are moving to conjugate products. Japan replaced the 23-valent polysaccharide vaccine with PCV20 for routine vaccination at age 65 from April 2026 [9]. Merck booked USD 263.0 million of CAPVAXIVE sales for July to September 2026, with growth from launches in Asia Pacific and Europe [6]. Each switch of this kind raises the value of a national tender without adding a single eligible person.
• Pooled procurement is growing in volume while unit prices fall. UNICEF supported 28 new vaccine introductions in 2025 and delivered 56.0 million HPV doses and 31.0 million malaria doses [2]. In October 2026 Gavi and UNICEF secured a malaria vaccine price of EUR 5.5 per dose, about 40.0% below the current level, with effect expected by early 2027 [23]. Suppliers to this channel must plan for rising dose counts at thinner margins.
• US recommendation changes are reshaping private-channel demand. Pfizer attributed a 30.0% fall in third-quarter 2026 Comirnaty revenue to narrower US vaccine recommendations [4]. The CDC also adopted individual decision-making for the hepatitis B birth dose in infants born to mothers who test negative for the virus in December 2025 [17]. Manufacturers now treat US policy as a demand variable to be forecast each season.

Regional Highlights

• In Europe, joint purchasing and outbreak response are both adding orders. The European Commission signed a four-year framework contract covering up to 24.0 million mRESVIA doses on behalf of six countries in July 2026, with no minimum purchase [5]. ECDC counted 2,335 measles cases across 30 EU and EEA countries in the year to August 2026, and 71.9% of cases with known status were unvaccinated [19]. Measles catch-up campaigns therefore run alongside long-term adult contracts in national budgets.
• In Asia Pacific, programme expansion and export manufacturing drive growth. The Korea Disease Control and Prevention Agency extended free influenza vaccination to children up to age 14 for the 2026 to 2027 season, delivered through about 23,000 contracted clinics [11]. SINOVAC reported that overseas revenue rose 82.3% in the first half of 2026 and reached 45.2% of its sales [32]. Serum Institute of India gained WHO prequalification for its quadrivalent HPV vaccine in October 2026, which opens UN agency procurement [25].

Vaccines Market Size and Forecast

Table 1: Vaccines Market Size and Forecast

Market size and forecast	Value
Market size in 2025	USD 54.5 billion
Estimated market size in 2026	USD 58.5 billion
Projected market size by 2036	USD 119.5 billion
CAGR from 2026 to 2036	7.4%

Source: Future Market Insights analysis of the vaccines market, 2026.

Analyst Perspective

“Vaccine buyers start from a funded schedule and an eligible age band, and only then compare products on price per completed course. Suppliers separate themselves through serotype coverage, vial presentation and the ability to deliver before a campaign opens. The main qualification risk is a change in a national recommendation, which can remove a whole cohort from the funded list within one season.”

- Anurag Sharma, Principal Consultant, FMI

How is the Vaccines Market segmented?

• By vaccine type: Inactivated, Live Attenuated, Recombinant, Toxoid, and Subunit & Conjugate.
• By valency: Monovalent and Multivalent.
• By route of administration: Injectable and Oral.
• By indication: Influenza, Pneumococcal Diseases, Human Papillomavirus, Meningococcal Diseases, Rotavirus, MMR, Hepatitis, DTP, and Polio.
• By distribution channel: Hospital Pharmacies, Institutional Sales, and Retail Pharmacies.
• By application: Human Use and Animal Use.
• By region: North America, Latin America, Europe, Asia Pacific, and Middle East and Africa.

Why does Human Use lead by Application in the Vaccines Market in 2026?

Human Use holds 68.2% of the Vaccines Market by application in 2026.

Publicly funded childhood schedules give human vaccines a recurring revenue base. WHO estimates three-dose DTP coverage at 85.0% for 2025, and it counts 13.5 million children who had no vaccine at all [1]. UNICEF alone moved 3.2 billion doses into 103 countries in 2025 on a vaccine spend of USD 2.4 billion [2]. Governments budget for these courses every year, so suppliers can plan capacity against known birth cohorts.

Adult and adolescent programmes add higher-value courses on top of that base. Merck's GARDASIL revenue reached USD 1,995.0 million during the third quarter of 2026, a rise of 14.0% on US public-sector purchasing and net pricing [6]. The UK Health Security Agency opened RSV vaccination to care home residents and adults aged 80 and over from April 2026 [10]. Each new cohort converts a licence into funded demand.

Animal Use holds the remaining 31.8% by application. Zoetis booked USD 1,040.0 million of vaccine revenue in the six months to June 2026, against USD 949.0 million a year earlier [12]. Merck Animal Health sales reached USD 1.7 billion over the same three months, with livestock growth led by poultry products [6]. Livestock and companion animal demand is covered in FMI's veterinary vaccines market report.

Table 2: Application, 2026 Share

Leading Share	2026 market share
Human Use	68.2%
All Other Segments Combined Share	31.8%

Source: Future Market Insights analysis of the vaccines market, 2026.

Why do Subunit & Conjugate Vaccines lead by Vaccine Type in the Vaccines Market in 2026?

Subunit & Conjugate vaccines account for 24.7% of the Vaccines Market by vaccine type in 2026.

Conjugate products have the highest value per dose in routine schedules. Pfizer's Prevnar family still earned USD 1,564.0 million between July and September 2026 after a 10.0% decline [4]. GSK's meningitis vaccines grew 21.0% to GBP 0.5 billion in the quarter to June 2026 [7]. Pneumococcal conjugates serve infants and older adults in the same tender cycle, which no other platform matches. Pricing for these products is analysed in FMI's pneumococcal vaccines market report.

Public schedules are also widening the serotype count they buy. Japan's health ministry now permits only PCV20 for routine older-adult vaccination and excludes PPSV23, PCV15 and PCV21 from the funded programme [9]. UNICEF delivered 175.3 million pneumococcal conjugate doses in 2025 [2]. Suppliers that win a schedule change can hold that position for several years.

Inactivated, Live Attenuated, Recombinant and Toxoid vaccines together hold the remaining 75.3% by vaccine type. Seasonal influenza is the largest inactivated product line at CSL Seqirus, where FLUAD sales reached USD 968.0 million in fiscal 2026 [29]. Merck's live attenuated MMR and varicella products earned USD 730.0 million in the September 2026 quarter on higher European demand [6]. FMI covers those products in its attenuated vaccines market report.

Table 3: Vaccine Type, 2026 Share

Leading Share	2026 market share
Subunit & Conjugate	24.7%
All Other Segments Combined Share	75.3%

Source: Future Market Insights analysis of the vaccines market, 2026.

Why do Injectable Products lead by Route of Administration in the Vaccines Market in 2026?

Injectable products represent 93.0% of the Vaccines Market by route of administration in FMI's 2026 assessment.

Nearly every licensed antigen and adjuvant combination is delivered by intramuscular or subcutaneous injection. UNICEF shipped 916.6 million syringes alongside its vaccine deliveries in 2025 [2]. Japan's routine PCV20 schedule specifies a single intramuscular dose [9]. Injection supplies and sharps handling therefore form part of every tender.

Oral vaccines are limited to a few pathogens and sell at low unit prices. UNICEF delivered 1.6 billion polio doses, 104.4 million rotavirus doses and 60.7 million cholera doses in 2025 [2]. Serum Institute of India supplied bivalent oral polio vaccine to UNICEF at 14.1 US cents per dose in the first quarter of 2026 [16]. Merck's oral ROTATEQ brought in USD 196.0 million for the three months to September 2026, down 4.0% [6]. High dose counts do not translate into high revenue for this route.

Oral products hold the remaining 7.0% by route of administration. Mucosal delivery remains a development route that FMI tracks separately in its nasal vaccines market report.

Table 4: Route of Administration, 2026 Share

Leading Share	2026 market share
Injectable	93.0%
All Other Segments Combined Share	7.0%

Source: Future Market Insights analysis of the vaccines market, 2026.

What are the key drivers restraints and opportunities?

Vaccine revenue follows the number of people a government agrees to fund and the product it specifies for them. The same rule that creates a cohort can remove it, so suppliers manage policy risk as closely as manufacturing risk.

Driver

Life-course immunisation is extending funded demand beyond infancy. The UK added adults aged 65 to 74 who are immunosuppressed or have chronic respiratory disease to its RSV programme from 1 September 2026 [10]. South Korea raised the upper age for free child influenza vaccination from 13 to 14 in its 2026 to 2027 programme [11]. WHO reports that first-dose HPV coverage among girls stood at 33.0% in 2025 [1]. Each extension creates a defined group of buyers that national programmes must supply every year.

Restraint

Policy reversals and budget limits can cut demand faster than new programmes add it. The US Department of Health and Human Services began winding down 22 mRNA vaccine development projects worth nearly USD 500.0 million in August 2025 [18]. The CDC then narrowed the list of vaccines recommended for all children to 11 diseases in January 2026 [3]. Pfizer linked a 30.0% fall in Comirnaty revenue to narrower US recommendations in its results for the quarter to 27 September 2026 [4]. Suppliers with US-weighted portfolios face the most exposure to these decisions.

Opportunity

New antigens with pooled funding offer long contracts to qualified suppliers. WHO counts 25 African countries offering malaria vaccination, with yearly targets above 10.0 million children [21]. A four-year evaluation found that about one in eight child deaths were averted among eligible children in the first three countries [22]. Bharat Biotech agreed a price of EUR 5.5 per dose for RTS,S with UNICEF, subject to WHO prequalification of a new manufacturing facility [23][24]. Bavarian Nordic agreed in March 2026 to transfer its chikungunya vaccine process to Serum Institute of India for supply to endemic countries [26]. Winning these programmes depends on prequalification timing and price discipline.

How do national recommendations and procurement rules affect vaccine purchasing?

A recommendation decides which products a public programme may buy. The CDC's revised childhood schedule keeps three categories, and all three remain covered by insurance without cost-sharing [3]. Japan's ministry lists PCV20 as the only vaccine permitted for routine older-adult pneumococcal vaccination from April 2026 [9]. A supplier left outside such a list loses the funded channel even if its licence stands.

Procurement rules then set price and timing. WHO's 2026 MI4A resource records vaccine purchases by 182 countries, covering product, presentation, price, volume and procurement channel [13]. UNICEF publishes the expected quarter of each vaccine tender for 2026 to 2029 [14]. Gavi's 2026 to 2030 market shaping strategy prioritises programme affordability, supply security and future markets for outbreak vaccines [15]. Manufacturers that align capacity with these calendars avoid idle lines and late deliveries.

What limits reliable vaccine supply and quality?

WHO prequalification is the gate to UN agency procurement. Serum Institute of India recorded its 32nd prequalification with CERVAVAC in October 2026 [25]. The lower RTS,S price agreed with UNICEF cannot apply until WHO prequalifies the new manufacturing site [23]. SK bioscience passed a WHO periodic GMP review of its Andong facility by documentary assessment in July 2026 [34]. Each step takes months and fixes the earliest date a supplier can ship.

Manufacturing campaigns and cold chain capacity set the ceiling. Bavarian Nordic completed its tick-borne encephalitis campaign during the first six months of 2026 and scheduled rabies production for the second half [27]. UNICEF delivered 153,972 vaccine carriers and cold boxes in 2025 to keep doses within temperature limits [2]. Seasonal timing adds a demand risk. Sanofi reported a 4.7% fall in second-quarter 2026 vaccine sales against a high influenza comparison [8]. A late batch or an early season can leave stock unsold.

Where can vaccine suppliers win additional business?

Adult RSV vaccination is the clearest open field. Pfizer's international Abrysvo revenue rose year on year from USD 68.0 million to USD 162.0 million in the quarter to September 2026 [4]. GSK's Arexvy sales more than doubled to GBP 0.2 billion in the second quarter [7]. Moderna signed the European Commission contract that caps supply at 24.0 million mRESVIA doses for six countries [28]. Combination products are the next step. Novavax earned a USD 125.0 million milestone when Sanofi began a Phase 3 trial of an influenza and COVID-19 combination vaccine in Europe [31]. Technology transfer opens a third route. SK bioscience agreed to supply its varicella vaccine process to Colombia's VECOL under a programme with investment of about USD 260.0 million over ten years [33].

Vaccines Market by Country (2026 to 2036)

Table 5: Vaccines Market Country Growth Forecast

Country	CAGR, 2026 to 2036
United States	6.7%
South Korea	6.6%
European Union	6.4%
United Kingdom	6.2%
Japan	6.1%

Source: Future Market Insights analysis of the vaccines market, 2026.

United States

US vaccine demand is now set as much by federal recommendations as by population size. The CDC's January 2026 schedule keeps 11 diseases in the category recommended for all children and places others under high-risk or shared decision-making [3]. The hepatitis B birth dose moved to individual decision-making in December 2025 for infants born to mothers who test negative [17]. These changes reach the Vaccines for Children programme and private insurance at the same time.

Company results show the split between product lines. Pfizer's Prevnar family dropped 10.0% to USD 1,564.0 million in July to September 2026 as adult and paediatric vaccination rates fell [4]. Its US Abrysvo revenue dropped 33.0% to USD 141.0 million in the same quarter [4]. Merck's GARDASIL rose 14.0% on favourable public-sector purchasing, while CAPVAXIVE lost US sales to lower adult pneumococcal uptake [6]. CSL Seqirus grew FLUCELVAX by 5.0% to USD 503.0 million on the US paediatric segment [29].

The 6.7% CAGR that FMI assigns to the United States for 2026 to 2036 rests on this mix of policy drag and product-led growth. High-value adult products and public HPV orders offset lower uptake elsewhere. Federal funding priorities add a second variable. HHS announced in August 2025 a wind-down of 22 mRNA development projects worth nearly USD 500.0 million and said it would shift the funding toward whole-virus and other platforms [18]. Suppliers should model each product against its own recommendation status instead of national birth rates. Those with protein, conjugate and cell-based lines hold the broadest set of funded channels through the decade.

South Korea

Korea's public programme buys through a dense clinic network and widens eligibility in defined steps. The Korea Disease Control and Prevention Agency opened the 2026 to 2027 free influenza season on 21 September 2026 for children needing two doses and for pregnant women [11]. Adults aged 75 and over followed from 12 October, with younger age bands opening in the following week. Children up to age 14 qualified for the first time, and about 23,000 contracted institutions deliver the doses [11]. Suppliers must ship strain-matched stock to that network before each start date. Expanding funded cohorts of this kind support Korean vaccine revenue growth of 6.6% a year across 2026 to 2036.

Domestic manufacturing gives Korean buyers a local source and an export base. SK bioscience passed WHO's three-year GMP review of its Andong facility in July 2026 and secured its first international procurement contract for SKYCellflu [34]. In May 2026 it signed a technology transfer agreement with Colombia's VECOL, starting with its varicella vaccine [33]. The agreement gives the company preferential rights for future vaccines made at the Colombian site.

The programme model concentrates demand in short windows, so distribution capacity matters more than brand. A growing export franchise adds a second source of revenue for local producers. A supplier that misses the September delivery date loses the season. Local firms also compete with imported influenza and pneumococcal products on price under public tenders. Export growth will depend on WHO prequalification for additional products and on partners such as VECOL reaching commercial scale.

European Union

EU vaccine purchasing combines national schedules with Commission-led joint contracts. The European Commission signed a framework with Moderna in July 2026 for as many as 24.0 million mRESVIA doses across four years, at the request of six countries and with no minimum order [5]. National programmes decide actual uptake, so the contract secures supply options and not revenue. Merck noted higher demand for its MMR and varicella products in certain European markets in its third-quarter 2026 results [6].

Measles control is adding short-notice orders. ECDC recorded 2,335 measles cases across 30 EU and EEA countries between September 2025 and August 2026, with 71.9% of cases with known status unvaccinated [19]. Catch-up campaigns need stock on short lead times. Together with joint adult contracts, these layers of demand give the European Union a 6.4% CAGR over 2026 to 2036 in FMI's forecast. Seasonal products are also moving upmarket. CSL Seqirus launched FLUAD in Germany and France during fiscal 2026 and grew the product by 5.0% to USD 968.0 million [29]. Sanofi plans Nuvaxovid launches in Germany from 2026 onward under its agreement with Novavax [30].

Animal vaccines are a further source of orders in the region. EMA recommended authorisation of Bovilis Lumpyvax against lumpy skin disease in cattle in October 2026 [35]. Suppliers that can serve both joint procurement and national tenders hold an advantage. The limit is budget discipline in member states, which keeps uptake of new adult vaccines below the ceiling set in Commission contracts.

United Kingdom

The UK buys vaccines centrally and extends eligibility by age band. The RSV programme that began for adults turning 75 in September 2024 added care home residents and people aged 80 and over from April 2026 [10]. From 1 September 2026 it covers adults aged 65 to 74 who are immunosuppressed or have chronic respiratory disease [10]. Pregnant women are offered the vaccine from week 28. Each extension is announced in advance, which lets suppliers plan deliveries to general practice.

Adolescent coverage is the second commercial theme. UKHSA reported year 10 HPV uptake at 75.5% among girls and 70.5% among boys for the 2024 to 2025 school year [20]. The programme now uses a single dose given in school, and young people remain eligible for free catch-up until their 25th birthday [20]. Lifting coverage means more doses within the existing contract and no new tender.

The pace of growth reflects a mature schedule where gains come from eligibility extensions and catch-up instead of new antigens. British vaccine revenue is therefore set to compound at 6.2% a year between 2026 and 2036, the second-lowest rate in this group. GSK, headquartered in the country, increased global vaccine sales 8.0% to GBP 2.3 billion over April to June 2026 [7]. Novavax lists the UK among planned Nuvaxovid launch markets for Sanofi from 2026 [30]. Price pressure under central procurement will cap the revenue gain from each added cohort.

Japan

Japan sets the exact product a municipality may use for each routine vaccine. The health ministry swapped PPSV23 for PCV20 from April 2026 in routine pneumococcal vaccination at age 65 and for high-risk adults aged 60 to 64 [9]. Eligibility did not change with the switch, so the gain for the supplier comes entirely from a higher-value product [9]. That decision moves national spending in one step, and specification-led purchasing of this kind holds Japan to a 6.1% CAGR over 2026 to 2036, the slowest of the five profiled markets.

Approvals in 2026 widened the adult respiratory choice set. GSK gained an expanded Japanese approval for Arexvy in adults aged 18 to 59 at increased risk of RSV [7]. Moderna reported Japanese approval of mNEXSPIKE with its second-quarter 2026 results [28]. Each product must then win a place in a routine or voluntary category to reach meaningful volume.

An ageing population raises the number of eligible older adults, but municipal budgets limit how many new products enter the routine list each year. Products outside the routine category rely on private payment and sell far fewer doses. Suppliers should therefore focus on the committee process that decides routine status instead of general promotion. Those that secure routine listing can expect stable orders for the life of that recommendation.

Who are the notable companies in the Vaccines Market?

Pfizer, Merck, GSK and Sanofi each report sizeable single-product vaccine franchises in their quarterly results. Pfizer's Prevnar family and Abrysvo brought in USD 1,564.0 million and USD 303.0 million respectively in the quarter ended 27 September 2026 [4]. Merck's GARDASIL reached USD 1,995.0 million in the same quarter [6]. GSK's Shingrix earned GBP 0.9 billion in the June 2026 quarter [7]. Sanofi reported vaccine sales of EUR 1.1 billion in that quarter and now leads Nuvaxovid commercial activity under its agreement with Novavax [8][31].

A second group competes on platform and seasonal supply. Moderna's net product sales were USD 94.0 million for April to June 2026, and it holds the EU RSV joint procurement contract [28]. CSL Seqirus earned USD 2.0 billion in fiscal 2026, with seasonal influenza sales up 4.0% despite lower US immunisation rates [29]. Bavarian Nordic raised its 2026 revenue outlook to about DKK 5.7 billion on travel vaccines and government orders for its mpox and smallpox vaccine [27].

High-volume manufacturers in India, China and Korea supply pooled procurement and emerging markets. Serum Institute of India cites annual capacity of 4.0 billion doses and gained its 32nd WHO prequalification in October 2026 [25]. Bharat Biotech is expected to supply RTS,S to UNICEF at EUR 5.5 per dose from early 2027 [24]. SINOVAC grew first-half 2026 sales by 12.9% to USD 147.1 million on varicella and polio exports [32]. SK bioscience is building a Latin American base through its VECOL agreement [33]. Zoetis and Merck Animal Health are the animal suppliers profiled here, and Zoetis alone earned USD 1,040.0 million from vaccines over January to June 2026 [12][6]. Buyers should weigh prequalification status, presentation and delivery record over portfolio size.

Key Developments in the Vaccines Market

• On 11 March 2026, Bavarian Nordic and Serum Institute of India expanded their partnership with a contract manufacturing agreement covering full technology transfer of the chikungunya VLP vaccine process to SII, to enable supply to endemic low- and middle-income countries [26].
• On 26 May 2026, SK bioscience signed a vaccine technology transfer and local manufacturing agreement with Colombia's state-owned VECOL, with SKYVaricella selected as the first product and preferential rights for later vaccines made at the site [33].
• On 9 July 2026, Moderna signed a joint procurement contract with the European Commission on behalf of six countries for up to 24.0 million doses of mRESVIA over up to four years, with no minimum purchase [5][28].

Key Players in the Vaccines Market

• Pfizer Inc.
• Merck & Co., Inc.
• GSK plc
• Sanofi SA
• Moderna, Inc.
• CSL Seqirus (CSL Limited)
• Bavarian Nordic A/S
• Novavax, Inc.
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech International Limited
• SINOVAC Biotech Ltd.
• SK bioscience Co., Ltd.
• Zoetis Inc.

Vaccines Market Report Scope

Table 6: Vaccines Market Report Scope

Coverage field	Report scope
Market definition	Revenue from preventive vaccine products sold for human and animal use through public tenders, hospital pharmacies and retail pharmacies. Syringes, administration fees, diagnostics and monoclonal antibodies are excluded.
Vaccine Type and Valency	Inactivated; Live Attenuated; Recombinant; Toxoid; Subunit & Conjugate; Monovalent; Multivalent
Route of Administration	Injectable; Oral
Indication	Influenza; Pneumococcal Diseases; Human Papillomavirus; Meningococcal Diseases; Rotavirus; MMR; Hepatitis; DTP; Polio
Distribution Channel	Hospital Pharmacies; Institutional Sales; Retail Pharmacies
Application	Human Use; Animal Use
Regions covered	North America; Europe; Asia Pacific; Latin America; Middle East and Africa
Profiled markets	United States; United Kingdom; European Union; Japan; South Korea
Companies covered	Pfizer Inc.; Merck & Co., Inc.; GSK plc; Sanofi SA; Moderna, Inc.; CSL Seqirus; Bavarian Nordic A/S; Novavax, Inc.; Serum Institute of India Pvt. Ltd.; Bharat Biotech International Limited; SINOVAC Biotech Ltd.; SK bioscience Co., Ltd.; Zoetis Inc.
Quantitative Units	USD billion

Source: Future Market Insights analysis of the vaccines market, 2026.

Vaccines Market Research Methodology

The vaccines assessment draws on WHO and UNICEF coverage and supply releases, national immunisation schedules, procurement announcements and manufacturer financial disclosures [1][2][3][4]. FMI measures annual revenue from vaccine products for human and animal use. Segment values are classified by application, vaccine type, route of administration, valency, indication and distribution channel. Country forecasts reflect funded eligibility, product specification, procurement channel and supplier approvals over the 2026 to 2036 period. Dose volumes, coverage rates and company revenue are reviewed as separate measures and are never summed into a market total.

Vaccines Market by Segments

Vaccines Market segmented by Vaccine Type:

• Inactivated
• Live Attenuated
• Recombinant
• Toxoid
• Subunit & Conjugate

Vaccines Market segmented by Valency:

• Monovalent
• Multivalent

Vaccines Market segmented by Route of Administration:

• Injectable
• Oral

Vaccines Market segmented by Indication:

• Influenza
• Pneumococcal Diseases
• Human Papillomavirus
• Meningococcal Diseases
• Rotavirus
• MMR
• Hepatitis
• DTP
• Polio

Vaccines Market segmented by Distribution Channel:

• Hospital Pharmacies
• Institutional Sales
• Retail Pharmacies

Vaccines Market segmented by Application:

• Human Use
• Animal Use

Vaccines Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Europe
  • European Union
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Nordics
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel
  • Sub-Saharan Africa

Research Sources and Bibliography

• [1] World Health Organization. (2026, July 15). Immunization coverage: Fact sheet.
• [2] UNICEF Supply Division. (2026, April). UNICEF Supply Annual Report 2025.
• [3] U.S. Centers for Disease Control and Prevention. (2026, January 5). CDC acts on presidential memorandum to update childhood immunization schedule.
• [4] Pfizer Inc. (2026, November 3). Pfizer reports third-quarter 2026 results. Form 8-K Exhibit 99, U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000125/pfe-9272026xex99.htm
• [5] European Commission. (2026, July 9). Commission signs joint procurement contract for vaccines to strengthen protection ahead of the 2026-2027 winter.
• [6] Merck & Co., Inc. (2026, October 29). Merck announces third-quarter 2026 financial results. https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2026-financial-results-highlights-multiple-milestones-advancing-broad-diverse-pipeline/
• [7] GSK plc. (2026, July 28). GSK delivers strong Q2 core results performance and continued momentum. https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum
• [8] Sanofi. (2026, July 30). Q2 2026: Double-digit sales growth and business EPS performance. https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767
• [9] Ministry of Health, Labour and Welfare, Japan. (2026, February 20). Pneumococcal vaccination for older adults: Routine vaccination from April 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/yobou-sesshu/vaccine/pneumococcus-senior/
• [10] UK Health Security Agency. (2026, August 11). Respiratory syncytial virus (RSV) programme: Information for healthcare professionals. https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals
• [11] Korea Disease Control and Prevention Agency. (2026, August 25). 2026-2027 season national influenza vaccination programme: Children up to age 14, pregnant women and adults aged 65 and over. https://kdca.go.kr/kdca/2848/subview.do?enc=Zm5jdDF8QEB8JTJGYmJzJTJGa2RjYSUyRjQyJTJGMzEyMzA4JTJGYXJ0Y2xWaWV3LmRvJTNG
• [12] Zoetis Inc. (2026, August). Form 10-Q for the quarterly period ended June 30, 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001555280/000155528026000040/zts-20260630.htm
• [13] World Health Organization. (2026, September 14). 2026 MI4A public vaccine purchase dataset. https://www.who.int/publications/m/item/2026-mi4a-public-vaccine-purchase-dataset
• [14] UNICEF Supply Division. (2026, June 17). Tender calendars: Vaccine tender issuance dates 2026-2029. https://www.unicef.org/supply/tender-calendars
• [15] Gavi, the Vaccine Alliance. (2026, July 28). Market shaping: Gavi market shaping strategy 2026-2030. https://www.gavi.org/our-work/market-shaping
• [16] UNICEF Supply Division. (2026, September 11). Oral polio vaccine (OPV) price data. https://www.unicef.org/supply/media/26046/file/OPV-vaccine-prices-11092026.pdf
• [17] U.S. Department of Health and Human Services. (2025, December 16). CDC adopts individual-based decision-making for hepatitis B immunization for infants born to women who test negative for the hepatitis B virus. https://www.hhs.gov/press-room/cdc-adopts-individual-based-decision-making-for-hepatitis-b-immunization-for-infants-born-to-women-who-test-negative-for-the-hepatitis-b-virus.html
• [18] U.S. Department of Health and Human Services. (2025, August 5). HHS winds down mRNA development under BARDA. https://hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html
• [19] European Centre for Disease Prevention and Control. (2026, October 9). Measles: European monthly monitoring, September 2025 to August 2026. https://www.ecdc.europa.eu/en/public-health-events/2011-eip-00003/2026-10-09
• [20] UK Health Security Agency. (2026, January 29). One in four school-leavers unprotected by HPV vaccine. https://www.gov.uk/government/news/1-in-4-school-leavers-unprotected-by-hpv-vaccine
• [21] World Health Organization. (2026, February 4). Malaria vaccines (RTS,S and R21): Questions and answers. https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
• [22] World Health Organization. (2026, May 8). New evidence confirms malaria vaccine saves child lives and will have high impact in wider rollout. https://www.who.int/news/item/08-05-2026-new-evidence-confirms-malaria-vaccine-saves-child-lives-and-will-have-high-impact-in-wider-rollout
• [23] UNICEF Supply Division. (2026, October 23). Gavi and UNICEF secure lower malaria vaccine price, saving US$50 million for childhood immunization programmes. https://www.unicef.org/supply/press-releases/gavi-and-unicef-secure-lower-malaria-vaccine-price-saving-us50-million-childhood
• [24] Bharat Biotech International Limited. (2026, October 23). Bharat Biotech announces equitable pricing for malaria vaccine. https://www.bharatbiotech.com/images/press/Bharat%20Biotech%20Announces%20Equitable%20Pricing%20for%20Malaria%20Vaccine.pdf
• [25] Serum Institute of India Pvt. Ltd. (2026, October 5). Serum Institute of India's HPV vaccine CERVAVAC receives WHO prequalification. https://www.seruminstitute.com/sii-HPV-Vaccine-Cervavac-receives-WHO-prequalification.php
• [26] Serum Institute of India Pvt. Ltd. (2026, March 11). Bavarian Nordic and Serum Institute of India expand strategic partnership with chikungunya vaccine manufacturing agreement. https://www.seruminstitute.com/Bavarian_Nordic_and_Serum_Institute_of_India_Expand_Strategic_Partnership_with_Chikungunya_Vaccine_Manufacturing_Agreement.php
• [27] Bavarian Nordic A/S. (2026, August 21). Interim report for the first half of 2026. https://www.bavarian-nordic.com/media/384557/260821-q2-results-en.pdf
• [28] Moderna, Inc. (2026, July 31). Moderna reports second quarter 2026 financial results and provides business updates. Form 8-K Exhibit 99.1, U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000147/exhibit9912026q2pressrelea.htm
• [29] CSL Limited. (2026, August 18). Full year results for the twelve months ended 30 June 2026. Australian Securities Exchange announcement. https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf
• [30] Novavax, Inc. (2026, August 6). Novavax reports second quarter 2026 financial results and operational highlights. https://ir.novavax.com/press-releases/2026-08-06-Novavax-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Highlights
• [31] Novavax, Inc. (2026, October 29). Novavax earns $125 million milestone as Sanofi launches Phase 3 influenza-COVID-19 combination vaccine trial in Europe. https://ir.novavax.com/press-releases/2026-10-29-Novavax-Earns-125-Million-Milestone-as-Sanofi-Launches-Phase-3-Influenza-COVID-19-Combination-Vaccine-Trial-in-Europe
• [32] SINOVAC Biotech Ltd. (2026, August 17). SINOVAC reports unaudited first half of 2026 financial results. https://www.sinovac.com/en-us/news/SINOVAC_Reports_Unaudited_First_Half_of_2026_Financial_Results
• [33] SK bioscience Co., Ltd. (2026, May 26). SK bioscience signs vaccine technology transfer and local manufacturing agreement with Colombia's VECOL. https://www.skbioscience.com/en/news/news_01_01?mode=2&id=352&page=1
• [34] SK bioscience Co., Ltd. (2026, July 9). WHO completes periodic GMP review of SK bioscience's Andong L HOUSE facility by documentary assessment. https://www.skbioscience.com/en/news/news_01_01?mode=2&id=361&page=1
• [35] European Medicines Agency. (2026, October 9). EMA recommends authorisation of veterinary vaccine for lumpy skin disease in cattle. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-veterinary-vaccine-lumpy-skin-disease-cattle
• [36] UNICEF Supply Division. (2026, October). Vaccine Industry Consultation 2026, Copenhagen, 20-22 October 2026. https://www.unicef.org/supply/vaccine-industry-consultation-2026